Researcher Profiles - Ozaki Saeko

写真a

Ozaki Saeko

Affiliation

Nippon Medical School Hospital, Department of Dermatology, Senior Assistant Professor

Profile

日本医科大学附属病院皮膚科医です。

External link

Research Areas

Life Science / Dermatology

Education

Nippon Medical School Graduate School

2014.4 - 2019.3

　 More details

researchmap
Nippon Medical School Medical School

2004.4 - 2010.3

　 More details

researchmap

Research History

Nippon Medical School

　 More details

researchmap
Nippon Medical School

　 More details

researchmap

Papers

同種造血幹細胞移植にてようやく寛解に至った難治性毛包向性菌状息肉症の1例

井渕善聖, 尾崎紗恵子, 魚住知美, 三神絵里奈, 由井俊輔, 山口博樹, 佐伯秀久, 船坂陽子

日本皮膚科学会雑誌 133 ( 5 ) 1412 - 1412 2023.5

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
Active Tuberculosis in a Patient Receiving Adalimumab for Psoriatic Arthritis and Chemoprophylaxis for Latent Tuberculosis Infection.

Shun Miyazaki, Kazue Fujita, Saeko Ozaki, Susumu Ichiyama, Michiko Ito, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 90 ( 6 ) 480 - 485 2023

　More details

Language：English Publishing type：Research paper (scientific journal)

Tumor necrosis factor (TNF) inhibitors, including adalimumab, are widely used to treat refractory psoriatic arthritis (PsA). Although isoniazid chemoprophylaxis is generally effective in preventing reactivation of latent tuberculosis infection (LTBI), prophylactic measures do not fully protect against development of active tuberculosis. We report a rare case of active tuberculosis despite chemoprophylaxis for LTBI in a patient receiving adalimumab for PsA. A 60-year-old Japanese woman who had received a diagnosis of psoriasis at age 35 years presented with arthralgia of the right hand, which she first noticed 2 months previously. Physical examination showed scattered erythematous papules and plaques with scales on her trunk, extremities, and scalp. Her right metacarpophalangeal and proximal interphalangeal joints were swollen and painful, and her right wrist and elbow were painful. PsA was diagnosed and adalimumab was initiated. Because an interferon-γ release assay (IGRA) showed a borderline result at screening, isoniazid was administered as chemoprophylaxis for LTBI. At 22 months after initiation of adalimumab, IGRA was positive and chest CT disclosed centrilobular nodules in both lungs and swelling of multiple lymph nodes. Culture of sputum at 24 months demonstrated Mycobacterium tuberculosis. Active tuberculosis was diagnosed, and treatment with a combination of isoniazid, rifampicin, ethambutol hydrochloride, and pyrazinamide was started. To ensure timely diagnosis and treatment of active tuberculosis, a tuberculosis expert should be consulted at an early stage, with regular screening and monitoring.

DOI： 10.1272/jnms.JNMS.2023_90-610

PubMed

researchmap
Change in Serum KL-6 Level during Biologic Treatment for Psoriasis.

Toshihiko Hoashi, Shun Miyazaki, Saeko Ozaki, Susumu Ichiyama, Michiko Ito, Naoko Kanda, Hidehisa Saeki

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 90 ( 2 ) 194 - 201 2023

　More details

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: We previously analyzed data from blood examination screenings, including serum Krebs von den Lungen (KL) -6 level, before starting biologic treatment for psoriasis in a real-world setting. However, we did not follow change in KL-6 level after the initiation of biologics. Furthermore, there has been no follow-up study of certolizumab pegol, risankizumab, or tildrakizumab. This study evaluated change in serum KL-6 levels in patients during treatment with biologics, including certolizumab pegol, risankizumab, and tildrakizumab. METHODS: We analyzed data from 111 patients. Change in KL-6 level was regarded as significant if it increased to greater than 500 U/mL at least once and if the maximum level after treatment with biologics was at least 1.5 times that of the baseline level. RESULTS: KL-6 level significantly changed during treatment with TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors in 9 (20.9%), 2 (6.3%), and 2 (5.6%) patients, respectively. Mean age, mean baseline KL-6 level, and frequency of TNF inhibitor use were higher in patients with a significant change in KL-6 level than those in patients without a significant change. Ten patients had minor interstitial changes on chest CT scans but no clinical signs suggesting interstitial pneumonia. CONCLUSIONS: Older patients with psoriasis and high baseline KL-6 levels must be carefully monitored during treatment with biologics, especially TNF inhibitors. Monitoring of KL-6 level and chest CT scans is necessary to exclude the possibility of drug-induced interstitial pneumonia.

DOI： 10.1272/jnms.JNMS.2023_90-207

PubMed

researchmap
Change in Antinuclear Antibody Titers during Biologic Treatment for Psoriasis.

Shun Miyazaki, Saeko Ozaki, Susumu Ichiyama, Michiko Ito, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 90 ( 1 ) 96 - 102 2023

　More details

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: We previously evaluated blood screening data, including antinuclear antibodies (ANA), before initiating biologic treatment for patients with psoriasis in a real-world setting. However, we did not analyze change in ANA titers after the start of biologics. No previous study has comprehensively investigated change in ANA titers over time in individual patients or the effectiveness of certolizumab pegol or tildrakizumab. OBJECTIVES: This study evaluated change in ANA titers in individual patients during treatment with biologics, including certolizumab pegol and tildrakizumab. METHODS: 111 patients were included in this study. Change in ANA was regarded as significant when the ANA titer was ×80 or more in patients with a previously undetectable ANA titer or when it increased by fourfold or more in those with a detectable ANA titer before treatment. RESULTS: The ratios of patients with a significant change in ANA titer who were treated with a tumor necrosis factor (TNF) inhibitor, interleukin (IL) -17 inhibitor, or IL-23 inhibitor were 34.9% (15/43), 0.0% (0/32), and 0.0% (0/36), respectively. There were 4 patterns of significant change in ANA titer: (i) an increase (n=8), (ii) a decrease after an increase (n=4), (iii) a decrease after an increase with a drug change (n=2), and (iv) an increase after a decrease after an increase (n=1). No symptom suggesting lupus syndrome was noted. CONCLUSIONS: ANA titers must be carefully monitored throughout treatment with biologics, especially TNF inhibitors, and the possibility of lupus-like syndrome should be excluded.

DOI： 10.1272/jnms.JNMS.2023_90-115

PubMed

researchmap
Two novel mutations in the ATP2C1 gene found in Japanese patients with Hailey-Hailey disease. International journal

Shun Miyazaki, Hajime Nakano, Maki Mizuno, Saeko Ozaki, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki

The Journal of dermatology 49 ( 6 ) 656 - 660 2022.3

　More details

Language：English Publishing type：Research paper (scientific journal)

Hailey-Hailey disease (HHD) is an autosomal dominant genodermatosis and the defective gene in HHD is ATP2C1, which encodes secretory pathway Ca2+ /Mn2+ ATPase type 1 (SPCA1). Here we report four Japanese HHD patients showing three kinds of mutations with premature termination codons in the ATP2C1 gene, including two novel ones. Patient 1 was a 39-year-old man with a novel heterozygous mutation, c.664dup in exon 8 (p.N215Kfs*26). Patient 2 was a 33-year-old man (the younger brother of patient 1) with the same mutation as patient 1. Patient 3 was a 55-year-old man with a previously reported heterozygous mutation, c.519dup in exon 7 (p.R174Tfs*4). Patient 4 was a 33-year-old woman with a novel heterozygous mutation, c.2640del in exon 27 (p.L881Ffs*10). The clinical characteristics of our four cases varied in disease severity and the response to treatment. The present cases enrich the database of mutational analysis for HHD.

DOI： 10.1111/1346-8138.16353

PubMed

researchmap
Real-world blood examination screening data before initiation of biologics for psoriasis patients. International journal

Saeko Ozaki, Susumu Ichiyama, Michiko Ito, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki

The Journal of dermatology 49 ( 5 ) 534 - 538 2022.2

　More details

Language：English Publishing type：Research paper (scientific journal)

Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes. Biologics have been available for the treatment of patients with refractory psoriasis since 2010 in Japan, and as of December 2021, 10 biologics were available. The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis recommends blood examination tests for antinuclear antibodies (ANA), Krebs von den Lugen (KL)-6, hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis C virus (HCV) antibodies, HIV antibodies, human T-cell leukemia virus (HTLV)-1 antibodies, β-D-glucan, and the T-cell spot (T-SPOT) test before initiation of biologics at screening. In this study, we evaluated the use of biologics for 127 psoriasis patients and the blood examination screening data before initiation of biologics in the real-world setting. Tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors and IL-23 inhibitors were initiated for 54 (42.5%), 36 (28.3%), and 37 (29.1%) patients, respectively. The numbers of patients positive for ANA, HBsAg, HBsAb, HBcAb, HCV antibody, HIV antibody, HTLV-1 antibody, and T-SPOT were 27 (21.3%), 0 (0%), 22 (17.3%), 20 (15.7%), three (2.4%), zero (0%), one (0.8%), and 4 (3.1%), respectively. The numbers of patients whose KL-6 and β-D-glucan levels were higher than the reference values were seven (5.5%) and seven (5.5%), respectively. In the real-world setting, it is sometimes unavoidable to use biologics for those patients with abnormal data although careful monitoring is necessary.

DOI： 10.1111/1346-8138.16333

PubMed

researchmap
鼠径管に発生した異所性子宮内膜症の1例

63 ( 12 ) 1964 - 1967 2021.11

　More details

DOI： 10.18888/hi.0000002969

CiNii Books

CiNii Research

researchmap

Other Link： https://search.jamas.or.jp/link/ui/2022045474
鼠径管に発生した異所性子宮内膜症の1例

梅田由貴, 帆足俊彦, 江崎英子, 市山進, 尾崎紗恵子, 市川侑里, 大滝薫, 加茂沢子, 明樂重夫, 青木悠人, 船坂陽子, 佐伯秀久

皮膚科の臨床 63 ( 12 ) 1964 - 1967 2021.11

　More details

Language：Japanese Publisher：金原出版(株)

＜文献概要＞32歳,女性。1年前より月経前後や咳嗽時に右鼠径部に疼痛が誘発される皮下腫瘤を自覚した。右鼠径部に有痛性・弾性硬の皮下腫瘤を触知し,MRIでは同部位に多房性の腫瘤を認めた。確定診断のため切除を行ったところ,腫瘤は鼠径管内に存在した。病理組織検査では,線維筋性組織内に島状の内膜様組織が散見され,鼠径管内に生じた子宮内膜症と診断した。異所性子宮内膜症に特徴的な画像所見はなく,月経随伴症状を伴わない場合,鼠径部に腫瘤を生じる他の疾患との鑑別が困難であり,治療の主体となる診療科の決定が困難な場合がある。生殖年齢女性の鼠径部に有痛性腫瘤がある場合は,本疾患を考慮し,詳細な問診を行う必要があると考える。

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2021&ichushi_jid=J01266&link_issn=&doc_id=20211122060049&doc_link_id=10.18888%2Fhi.0000002969&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000002969&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif
Region-specific changes in brain kisspeptin receptor expression during estrogen depletion and the estrous cycle. International journal

Saeko Ozaki, Shimpei Higo, Kinuyo Iwata, Hidehisa Saeki, Hitoshi Ozawa

Histochemistry and cell biology 152 ( 1 ) 25 - 34 2019.7

　More details

Language：English Publishing type：Research paper (scientific journal)

Kisspeptin acts as a potent neuropeptide regulator of reproduction through modulation of the hypothalamic-pituitary-gonadal axis. Previous studies revealed sex differences in brain expression patterns as well as regulation of expression by estrogen. Alternatively, sex differences and estrogen regulation of the kisspeptin receptor (encoded by Kiss1r) have not been examined at cellular resolution. In the current study, we examined whether Kiss1r mRNA expression also exhibits estrogen sensitivity and sex-dependent differences using in situ hybridization. We compared Kiss1r mRNA expression between ovariectomized (OVX) rats and estradiol (E2)-replenished OVX rats to examine estrogen sensitivity, and compared expression between gonadally intact male rats and female rats in diestrus or proestrus to examine sex differences. In OVX rats, E2 replenishment significantly reduced Kiss1r expression specifically in the hypothalamic arcuate nucleus (ARC). A difference in Kiss1r expression was also observed between diestrus and proestrus rats in the hypothalamic paraventricular nucleus (PVN), but not in the ARC. Thus, estrogen appears to have region- and context-specific effects on Kiss1r expression. However, immunostaining revealed minimal colocalization of estrogen receptor alpha (ERα) in Kiss1r-expressing neuronal populations of ARC and PVN, indicating indirect or ERα-independent regulation of Kiss1r expression. Surprisingly, unlike the kisspeptin ligand, no sexual dimorphisms were observed in either the brain distribution of Kiss1r expression or in the number of Kiss1r-expressing neurons within enriched brain nuclei. The current study reveals marked differences in regulation between kisspeptin and kisspeptin receptor, and provides an essential foundation for further study of kisspeptin signaling and function in reproduction.

DOI： 10.1007/s00418-018-01767-z

PubMed

researchmap
Melanotic Malignant Melanoma in Oculocutaneous Albinism Type 4. International journal

Saeko Ozaki, Yoko Funasaka, Yohei Otsuka, Satomi Oyama, Michiko Ito, Shin-Ichi Osada, Takashi Ueno, Ken Okamura, Yutaka Hozumi, Tamio Suzuki, Seiji Kawana, Hidehisa Saeki

Acta dermato-venereologica 97 ( 2 ) 287 - 288 2017.2

　More details

Language：English Publishing type：Research paper (scientific journal)

DOI： 10.2340/00015555-2489

PubMed

researchmap
Follicular lymphoma presenting follicular papules in the skin: A case report. International journal

Saeko Ozaki, Yoko Funasaka, Ai Shimizu, Mai Kawarasaki, Akiko Kanzaki, Yoko Matano, Ayako Futagami, Hiroki Yamaguchi, Yuichi Sugisaki, Hidehisa Saeki

The Journal of dermatology 44 ( 1 ) 111 - 113 2017.1

　More details

Language：English

DOI： 10.1111/1346-8138.13441

PubMed

researchmap
Extranodal natural killer/T-cell lymphoma, nasal type, presenting with altered CD56 expression: A case report. International journal

Saeko Ozaki, Yoko Funasaka, Kyoko Tsuruta, Tomoki Kubota, Takemitsu Matayoshi, Takashi Ueno, Hidehisa Saeki

The Journal of dermatology 42 ( 10 ) 1022 - 3 2015.10

　More details

Language：English

DOI： 10.1111/1346-8138.13018

PubMed

researchmap
Granulocyte colony-stimulating factor-induced granulomatous dermatitis with enlarged histiocytes clinically manifesting as painful edematous nodules with high fever similar to Sweet's syndrome. International journal

Saeko Ozaki, Yoko Funasaka, Masaya Takubo, Takemitsu Matayoshi, Takashi Ueno, Toshio Asayama, Hidehisa Saeki

The Journal of dermatology 42 ( 4 ) 414 - 7 2015.4

　More details

Language：English Publishing type：Research paper (scientific journal)

A 72-year-old woman with a history of diffuse large B cell lymphoma and recent recurrence visited our department complaining of several painful edematous nodules with blisters on her face. She had iteratively developed cutaneous eruptions after every treatment with granulocyte colony-stimulating factor (G-CSF) for neutropenia, and each time the eruption improved after the cessation of the G-CSF treatment. The blisters became crusty and the skin lesions slightly improved, but on the 24th hospital day, the eruption formed painful erythematous nodules with erosion, and the patient also developed a high fever of up to 38°C. A biopsy specimen showed a dermal infiltrate of increased and enlarged plump histiocytes, some of which indicated karyomitosis with a small number of lymphocytes. No increase in the number of eosinophils or neutrophils was noted. These eruptions lasted for 15 days and disappeared with the recovery of the peripheral blood count and attendant cessation of G-CSF. We diagnosed this case as G-CSF-induced granulomatous dermatitis with enlarged histiocytes. Several cases with maculopapular rash and dermal inflammatory infiltrate composed of interstitially arranged large histiocytes have been reported. However, to the best of our knowledge, this is the first case report of G-CSF-induced granulomatous dermatitis with enlarged histiocytes clinically manifesting as painful edematous nodules with a high fever, similar to Sweet's syndrome. We speculated that the infiltrating cells were not neutrophils but histiocytes, presumably because of agranulocytosis.

DOI： 10.1111/1346-8138.12772

PubMed

researchmap

▼display all

Misc.

エキシマレーザーとエキシマライトの光到達深度の差異、ならびに色素幹細胞への活性化に関わる作用の検討

井渕善聖, 尾崎紗恵子, 佐伯秀久, 船坂陽子

日本医科大学医学会雑誌 17 ( 4 ) 282 - 282 2021.10

　More details

Language：Japanese Publisher：日本医科大学医学会

researchmap
ダウン症に合併したEruptive syringomaに炭酸ガスレーザーと色素レーザーを用いた一例

尾崎紗恵子, 魚住知美, 奈古利江, 荻田あづさ, 佐伯秀久, 船坂陽子

Aesthetic Dermatology 31 ( 2 ) 220 - 220 2021.7

　More details

Language：Japanese Publisher：(一社)日本美容皮膚科学会

researchmap
エキシマレーザーとエキシマライトの光到達深度の差異、ならびに色素幹細胞への活性化に関わる作用の検討

井渕善聖, 尾崎紗恵子, 井上由貴, 前島真帆, 佐伯秀久, 船坂陽子

Aesthetic Dermatology 31 ( 2 ) 197 - 197 2021.7

　More details

Language：Japanese Publisher：(一社)日本美容皮膚科学会

researchmap
308nmエキシマレーザーで治療した尋常性白斑の25例エキシマレーザーの有効性について

尾崎紗恵子, 井渕善聖, 井上由貴, 前島真帆, 魚住知美, 佐伯秀久, 船坂陽子

日本皮膚科学会雑誌 131 ( 5 ) 1361 - 1361 2021.5

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
尋常性白斑に対するエキシマレーザー治療

魚住知美, 井渕善聖, 尾崎紗恵子, 佐伯秀久, 船坂陽子

Aesthetic Dermatology 30 ( 2 ) 216 - 216 2020.9

　More details

Language：Japanese Publisher：(一社)日本美容皮膚科学会

researchmap
爪甲破壊を伴った右拇趾爪甲下化膿性肉芽腫の1例

魚住知美, 帆足俊彦, 井上由貴, 大瀧薫, 加茂沢子, 市川有里, 市山進, 尾崎紗恵子, 江崎英子, 船坂陽子, 佐伯秀久, 安齋眞一, 川端康浩

日本皮膚科学会雑誌 130 ( 4 ) 625 - 625 2020.4

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
浅側頭動脈に生じたMonckeberg型動脈硬化症の1例

濱田里沙, 帆足俊彦, 加茂沢子, 石原優里, 魚住知美, 岩井麻里子, 尾崎紗恵子, 江崎英子, 船坂陽子, 佐伯秀久, 安齋眞一

日本皮膚科学会雑誌 130 ( 4 ) 638 - 638 2020.4

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
鼠経管に発生した異所性子宮内膜症の1例

井上由貴, 帆足俊彦, 江崎英子, 市山進, 尾崎紗恵子, 市川侑里, 大滝薫, 加茂沢子, 船坂陽子, 佐伯秀久, 明樂重夫, 青木悠人

日本皮膚科学会雑誌 130 ( 4 ) 627 - 627 2020.4

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
腎盂癌・膀胱癌に対しPembrolizumabを導入し、落葉状天疱瘡が悪化した1例

加茂沢子, 帆足俊彦, 萩野哲平, 山崎香里, 市山進, 尾崎紗恵子, 高山良子, 船坂陽子, 佐伯秀久, 遠藤勇気, 近藤幸尋

日本皮膚科学会雑誌 130 ( 1 ) 58 - 58 2020.1

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
ラットの脳におけるKisspeptin Receptorの発現の雌雄差およびエストラジオールに対する応答性

尾崎紗恵子, 肥後心平, 岩田衣世, 佐伯秀久, 小澤一史

日本組織細胞化学会総会・学術集会講演プログラム・予稿集 59回 72 - 72 2018.9

　More details

Language：Japanese Publisher：日本組織細胞化学会

researchmap
組織細胞化学を用いた神経系研究のup-date Kisspeptinニューロンの作用と脳内Kisspeptin受容体マッピング

肥後心平, 尾崎紗恵子, 飯島典生, 小澤一史

日本組織細胞化学会総会・学術集会講演プログラム・予稿集 57回 31 - 31 2016.9

　More details

Language：Japanese Publisher：日本組織細胞化学会

researchmap
皮膚に毛孔一致性丘疹を呈した濾胞性リンパ腫

尾崎紗恵子, 船坂陽子, 新井悠江, 清水愛, 川原崎麻以, 神崎亜希子, 亦野蓉子, 秋山美知子, 二神綾子, 佐伯秀久

Skin Cancer 30 ( 2 ) 137 - 137 2015.11

　More details

Language：Japanese Publisher：(一社)日本皮膚悪性腫瘍学会

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J02197&link_issn=&doc_id=20160222370028&doc_link_id=10.5227%2Fskincancer.30.137&url=https%3A%2F%2Fdoi.org%2F10.5227%2Fskincancer.30.137&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_2.gif
皮膚に毛孔一致性丘疹を呈した濾胞性リンパ腫

尾崎紗恵子, 船坂陽子, 新井悠江, 清水愛, 川原崎麻以, 神崎亜希子, 亦野蓉子, 秋山美知子, 二神綾子, 佐伯秀久

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 31回 125 - 125 2015.7

　More details

Language：Japanese Publisher：(一社)日本皮膚悪性腫瘍学会

researchmap
有色素性悪性黒色腫を生じた眼皮膚白皮症4型

尾崎紗恵子, 船坂陽子, 大塚洋平, 伊藤路子, 長田真一, 上野孝, 岡村賢, 穂積豊, 鈴木民夫, 佐伯秀久

日本皮膚科学会雑誌 125 ( 4 ) 928 - 928 2015.4

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
診断確定に至るまでに数回の生検を要したNK/T細胞リンパ腫の1例

尾崎紗恵子, 船坂陽子, 木下侑里, 又吉武光, 久保田智樹, 上野孝, 川名誠司, 佐伯秀久

日本皮膚科学会雑誌 125 ( 1 ) 110 - 110 2015.1

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
G-CSF製剤に誘発されたgranulomatous dermatitisの1例

尾崎紗恵子, 船坂陽子, 田久保匡哉, 又吉武光, 上野孝, 佐伯秀久, 朝山敏夫

日本皮膚科学会雑誌 124 ( 10 ) 1967 - 1967 2014.9

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap
【細菌・抗酸菌・スピロヘータ感染症】妊婦梅毒の1例

尾崎紗恵子, 上野孝, 山下裕子, 川名誠司

皮膚科の臨床 55 ( 11 ) 1377 - 1379 2013.11

　More details

Language：Japanese Publisher：金原出版(株)

25歳女性。妊娠11週時の梅毒スクリーニング検査ではRPR・TPHAともに陰性であったが、妊娠25週時から陰部に潰瘍を伴った結節が認められ、産科から硝酸オキシコナゾール外用剤が処方されていた。以後、妊娠27週時に夫の梅毒罹患が判明し、RPR値は32倍、TPHA値は80倍であり、第I期梅毒と診断された。対処としてアモキシシリン(1000mg/日)の内服を行なったところ、2週間後には会陰部病変とリンパ節腫脹は消失、加療5週目にはPRP値は8倍まで低下した。だが、その後も本人の希望で出産時までアモキシシリンの内服が継続され、妊娠38週1日目に骨盤位のため帝王切開にて3354gの女児を出産した。尚、新生児の梅毒血清反応は出生時RPR値が2倍、TPHA値が80倍で、Fluorescent treponemal antibody-absorption(FTA-Abs)-IgM値は陰性で、先天性梅毒ではないと判断、FTA-Abs-IgM陰性が判明するまでベンジルペニシリンカリウム15万単位を1日2回投与された。

researchmap
妊婦梅毒の1例

尾崎紗恵子, 山下裕子, 上野孝, 川名誠司

日本皮膚科学会雑誌 123 ( 2 ) 186 - 186 2013.2

　More details

Language：Japanese Publisher：(公社)日本皮膚科学会

researchmap

▼display all

Awards

第114回日本皮膚科学会総会,ポスター賞

2015.6 日本皮膚科学会

　More details

researchmap